White Diamond Research says Pulse Biosciences (PLSE)’ Nano-Pulse Stimulation technology “has a long history of commercial failures which contradict the company’s sky-high valuation of $1B+.” In a research report posted on its website, White Diamond argues Pulse’s new application in benign thyroids will be “another dead end.” The company’s “history of failure will likely continue,” the firm contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: